Malmström, Vivianne
Catrina, Anca I.
Klareskog, Lars
Article History
First Online: 5 December 2016
Change Date: 30 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41577-022-00741-0
Competing interests
: The authors have received financial support (to their host institution, the Karolinska Institute) from the following companies: Janssen, Pfizer, Bristol-Myers Squibb (BMS), AbbVie, UCB, Sobi and Roche. Support has also been given to the Rheumatology Unit of the Karolinska Institute within the projects BTCure and ULTRA-DD, which are supported by the Innovative Medicines Initiative of the European Union (EU) and by several companies (Janssen, UCB, GlaxoSmithKline, Pfizer and Thermo Fisher) according to EU rules. V.M., A.I.C. and L.K. have all given lectures supported by pharmacological companies (BMS, Pfizer, Janssen, Sobi and Novartis) within their duties of the Karolinska Institute (and with financial compensation to the Karolinska Institute). V.M., A.I.C. and L.K. have filed patent applications related to the therapeutic use of CXCL8 and peptidyl-arginine deiminase blockade. V.M. and L.K. have also filed patent applications related to tolerization with citrullinated peptides (supported by a European Research Council Proof of Concept (ERC PoC) grant). All patent applications are handled within a research and innovation foundation named Vectis.